Roche's Evrysdi approved by European Commission as first and only at home treatment for spinal muscular atrophyGlobeNewsWire • 03/30/21
Roche receives positive CHMP opinion for Tecentriq as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancerGlobeNewsWire • 03/26/21
Roche commences tender offer for all shares of GenMark Diagnostics, Inc. for $24.05 per share in cashGlobeNewsWire • 03/25/21
Ionis Pharma Stock Is Trading Lower After Roche Drops Huntington's Disease Trial With TominersenBenzinga • 03/23/21
Roche launches new high throughput configurations for cobas pro integrated solutions to increase testing efficiencyGlobeNewsWire • 03/23/21
New phase III data shows investigational antibody cocktail casirivimab and imdevimab reduced hospitalisation or death by 70% in non-hospitalised patients with COVID-19GlobeNewsWire • 03/23/21
Roche provides update on tominersen programme in manifest Huntington's diseaseGlobeNewsWire • 03/22/21
Genentech Provides Update on Tominersen Program in Manifest Huntington's DiseaseBusiness Wire • 03/22/21
Roche's (RHHBY) Tecentriq Meets Primary Goal in Lung Cancer StudyZacks Investment Research • 03/22/21
Pivotal Phase III study shows Roche's Tecentriq helped people with early lung cancer live longer without their disease returningGlobeNewsWire • 03/22/21
Pivotal Phase III Study Shows Genentech's Tecentriq Helped People With Early Lung Cancer Live Longer Without Their Disease ReturningBusiness Wire • 03/22/21
Roche launches cobas pure integrated solutions analyser to help simplify operations in small to medium sized labsGlobeNewsWire • 03/17/21
Roche launches SARS-CoV-2 variant test to help monitor emerging coronavirus mutationsGlobeNewsWire • 03/16/21
New two-year data show Roche's Evrysdi (risdiplam) continues to demonstrate improvement or maintenance of motor function in people aged 2-25 with Type 2 or Type 3 Spinal Muscular Atrophy (SMA)GlobeNewsWire • 03/16/21
New 2-Year Data Show Genentech's Evrysdi (risdiplam) Continues to Demonstrate Improvement or Maintenance of Motor Function in People Aged 2-25 With Type 2 or Type 3 Spinal Muscular Atrophy (SMA)Business Wire • 03/16/21
GenMark Shares Surge After Roche Announces $1.8 Billion Deal for Molecular Test MakerBarrons • 03/15/21